KORU Medical Systems (KRMD) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
16 Nov, 2026Company overview and business model
Develops, manufactures and commercializes large-volume subcutaneous infusion solutions for drug delivery, subject to FDA quality and regulatory requirements and international quality standards.
FREEDOM System includes FREEDOM60 and FreedomEdge syringe infusion drivers, Precision Flow Rate Tubing and HIgH-Flo safety needle sets for home and alternate-care infusions.
Use of proceeds and capital allocation
Net proceeds will be allocated as specified in each prospectus supplement; potential uses include acquisitions, debt repayment or refinancing, working capital and capital expenditures.
No cash dividends are planned in the foreseeable future; available funds are intended for operations, and the KeyBank credit facility restricts cash dividends and distributions.
Risk factors and disclosures
Identified risks include competition, insurance reimbursement, FDA and international regulation, healthcare policy, R&D outcomes, product demand and market acceptance, technology changes, quality and approvals.
Additional exposures include capital access, credit-facility covenants, patents, cybersecurity, supplier performance, distributor preference, key-personnel retention, litigation, tax and labor laws, trade policy and economic conditions.
Forward-looking statements reflect estimates and assumptions as of November 13, 2026; actual results may differ materially, and updates are not undertaken except as required by law.
Latest events from KORU Medical Systems
- Recurring SCIg revenue and a broader drug pipeline underpin growth toward $48M–$48.5M in FY2026.KRMD
Corporate presentation - Q3 growth and new market initiatives underpin the path toward $100 million in revenue.KRMD
Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum - Q3 revenue and margins rose, returning results to profit as FY26 guidance increased.KRMD
Q3 2026 - Accelerating growth in subcutaneous drug delivery with robust 2026 financial outlook.KRMD
Conference presentation - Guidance for FY2026 targets $47.5–$48.5M revenue and 15–18% growth, driven by innovation and expansion.KRMD
Corporate presentation - Q2 2026 revenue up 18%, gross margin 65.1%, and net income positive on strong global growth.KRMD
Q2 2026 - Strong recurring revenue and pipeline expansion drive double-digit growth in SC drug delivery.KRMD
Investor presentation - Q1 2026 revenue up 22% to $11.8M, improved margins, and strong full-year outlook reaffirmed.KRMD
Q1 2026 - Q3 revenue up 17% to $8.2M, gross margin 63.4%, and guidance raised for 2024.KRMD
Q3 2024